We regularly have new studies that we are recruiting for. If you don’t see something that you qualify for right now, please call Caitlin at 952-993-9605 to be contacted about future studies.
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes (SURPASS-3)
Principal Investigator: Thomas Martens, MD
Study Sponsor: Eli Lilly and Company
Location: International Diabetes Center
Purpose of study: This study will test for differences in blood sugars for people with type 2 diabetes who are using one of two different medications in addition to their usual diabetes medications. One is the investigational study medication, the other is a drug that is FDA approved for use with type 2 diabetes. Participants will be randomly assigned to receive one of these two medications. This study is designed for people with type 2 diabetes who are having trouble controlling their blood sugars with their current treatment. Past research with the study medication has shown an improvement in A1c and body weight.
Inclusion Criteria:
– The study is accepting males and females ages 18 and older who:
– Have type 2 diabetes
– Are taking only pills for treating their diabetes
– Have an A1C between 7.0-10.5%
– Meet other study specific requirements
Study Contact:
Caitlin Hasledalen
(952) 993-9605
IDCResearch@ParkNicollet.com
Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System (The 321 Study)
Principal Investigator: Anders Carlson, MD
Study sponsor: Medtronic
Locations: International Diabetes Center
Purpose of study: This study will test a new insulin pump system-the Medtronic Advanced Hybrid Closed Loop System (AHCL). This system consists of an insulin pump, a glucose sensor, and a transmitter. The system uses continuous glucose sensor information to tell the insulin pump how much insulin to infuse automatically to help control glucose levels in people who have type 1 diabetes. AHCL includes an updated version of the control mechanism in the currently available 670G insulin pump for the management of diabetes. The purpose of this study is to test how the AHCL system works for participants with type 1 diabetes.
Inclusion Criteria:
The study is accepting males and females ages 7-75 years old who:
– Have type 1 diabetes and have used an insulin pump for at least 6 months
– Have a hemoglobin A1c less than 10%
– Are willing and able to upload glucose and pump data between visits
– Meet other study specific requirements
Study Contact:
Caitlin Hasledalen
(952) 993-9605
IDCResearch@ParkNicollet.com
Type 2 Diabetes (T2D) Basal Insulin Users: The Mobile Study (MOBILE)
Principal Investigator: Thomas Martens, MD
Study Sponsor: Dexcom, Inc.
Location: International Diabetes Center
Purpose of Study: The purpose of this study is to see if blood glucose control is different using a continuous glucose monitor (CGM) compared to those who use a blood glucose meter, for people who have type 2 diabetes and are taking insulin injections every day. A CGM is a device that measures glucose levels every 5 minutes. The study will be using the Dexcom G6 CGM system. The study team will work with participants’ usual health care providers, giving information about their study glucose and options for improving their diabetes management.
Inclusion Criteria:
The study is accepting men and women ages 30 or older who:
– Have type 2 diabetes and are taking long-acting insulin injections every day
– Have an A1C of 8.0-11.5%
– Have not used a personal continuous glucose monitor (CGM) in the past 6 months and are willing to use a CGM during the study
– Have a smart phone and willing to use a phone app
– Meet other study specific requirements
Caitlin Hasledalen
(952) 993-9605
IDCResearch@ParkNicollet.com
